Hasan Jafri's Net Worth
-$20.1 Thousand
Who is Hasan Jafri?
Hasan Jafri does not have any significant net worth to report based on the numbers we have. This is based on reported shares in Aridis Pharmaceuticals, Inc..
SEC CIK
Hasan Jafri's CIK is 0001815352
Past Insider Trading and Trends
2021 was Hasan Jafri's most active year for acquiring shares with 5 total transactions. Hasan Jafri's most active month to acquire stocks was the month of August. 2023 was Hasan Jafri's most active year for disposing of shares, totalling 1 transactions. Hasan Jafri's most active month to dispose stocks was the month of May. 2021 saw Hasan Jafri paying a total of $21,147.00 for 45,100 shares, this is the most they've acquired in one year. In 2023 Hasan Jafri cashed out on 10,000 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Aridis Pharmaceuticals, Inc. (ARDS) Snapshot price: $0.0719
Chief Medical OfficerHasan Jafri owns 15,100 units of Common Stock which is worth $1,085.69. From 2020 to 2023 Hasan Jafri acquired a total of 15,100 shares in Aridis Pharmaceuticals, Inc. at a cost of $21,147.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 18
| |||
Form 4
| +196.08% | 10K |
—
|
—
| 15.1K |
May 4 - Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 4
|
∞
| 5.1K |
$4.15 | $21,147.00 | 5.1K |
Sep 3 - Sep 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||